Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Recent & Breaking News (TSXV:NGEN)

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Newsfile 7 days ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Newsfile November 7, 2024

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Newsfile September 30, 2024

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Newsfile September 20, 2024

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Newsfile September 16, 2024

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Newsfile August 27, 2024

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Newsfile August 22, 2024

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Newsfile August 6, 2024

NervGen Pharma Grants Stock Options

Newsfile August 2, 2024

NervGen Pharma Appoints Neil Klompas to Board of Directors

Newsfile July 22, 2024

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

Newsfile June 25, 2024

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Newsfile June 20, 2024

NervGen Pharma Grants Stock Options

Newsfile June 6, 2024

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Newsfile June 5, 2024

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

Newsfile May 17, 2024

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

Newsfile May 16, 2024

NervGen Files Management Information Circular and Announces Board of Directors Transition

Newsfile May 7, 2024

NervGen Engages Russo Partners LLC to Provide Public Relations Services

Newsfile April 25, 2024

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Newsfile April 17, 2024

NervGen Completes $23 Million Bought Deal Financing

Newsfile March 28, 2024